Alvotech (formerly Oaktree Acquisition Corp. II) is a biotech company, founded by Robert Wessman.Alvotech are 800 professionals across multiple countries,focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer.
CEO： Mr. Mark Levick
Listing Date： 09/17/2020